| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 25, 2002
Accepted on December 20, 2002
From the Department of Biochemistry (R.J.S., S.P.A.M.), University of Otago, Dunedin, New Zealand; Russell Grimwade School of Biochemistry and Molecular Biology (M.A.P.), University of Melbourne, Victoria, Australia; and Department of Medicine (S.M.M.), Northwest Lipid Research Laboratories, University of Washington, Seattle, Wash.
* To whom correspondence should be addressed. E-mail: sally.mccormick{at}stonebow.otago.ac.nz.
Objective--We previously reported that human apolipoprotein B100 (apoB) amino acids 4330-4397 were important for the initial noncovalent binding to apolipoprotein(a) [apo(a)] that facilitates lipoprotein(a) [Lp(a)] assembly. In this study, we aimed to additionally define the apoB sequences within the 4330-4397 region that were important for the noncovalent binding to apo(a).
Methods and Results--Alignment of the human apoB4330-4397 sequence with mouse apoB, which also noncovalently binds apo(a), revealed stretches of similar sequence, including a lysine-rich sequence spanning apoB amino acids 4372-4392. Structural analysis of the apoB4372-4392 sequence using the WHEEL program predicted an amphipathic
-helix. Circular dichroism studies of a synthetic peptide spanning human apoB amino acids 4372-4392, both in the absence and presence of dimyristoylphosphatidylcholine, confirmed the
-helical nature of the sequence. We tested the ability of the apoB4372-4392 peptide to bind to apo(a) and found that the peptide bound to apo(a) with high affinity but not to Lp(a). The apoB4372-4392 peptide inhibited Lp(a) assembly in Lp(a) formation assays far more effectively than the lysine analogue,
-amino-n-caproic acid (IC50=40 µmol/L versus 10 mmol/L, respectively). Incorporation of the apoB4372-4392 peptide onto dimyristoylphosphatidylcholine vesicles yielded an even more effective inhibitor (IC50=4 µmol/L).
Conclusions--Our study shows that the apoB4372-4392 sequence mediates the initial noncovalent binding to apo(a) and has demonstrated that the apoB4372-4392 peptide is a novel and effective inhibitor of Lp(a) assembly.
This article has been cited by other articles:
![]() |
Y.-T. Wang, A. von Zychlinski, and S. P. A. McCormick Dimyristoylphosphotidylcholine induces conformational changes in apoB that lowers lipoprotein(a) J. Lipid Res., May 1, 2009; 50(5): 846 - 853. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Sharp, M. A. Perugini, S. M. Marcovina, and S. P. A. McCormick Structural features of apolipoprotein B synthetic peptides that inhibit lipoprotein(a) assembly J. Lipid Res., December 1, 2004; 45(12): 2227 - 2234. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Becker, P. M. Cook, T. G. Wright, and M. L. Koschinsky Quantitative Evaluation of the Contribution of Weak Lysine-binding Sites Present within Apolipoprotein(a) Kringle IV Types 6-8 to Lipoprotein(a) Assembly J. Biol. Chem., January 23, 2004; 279(4): 2679 - 2688. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Y. Y. Liu, R. Broadhurst, S. M. Marcovina, and S. P. A. McCormick Mutation of lysine residues in apolipoprotein B-100 causes defective lipoprotein[a] formation J. Lipid Res., January 1, 2004; 45(1): 63 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Marcovina, M. L. Koschinsky, J. J. Albers, and S. Skarlatos Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions Clin. Chem., November 1, 2003; 49(11): 1785 - 1796. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |